Stem Cell IV Therapy for Autoimmune Disease: Myth vs Mechanism
Clinics claim stem cell IV therapy can repair damaged tissue throughout the body, but the biology tells a more nuanced story. This article breaks down the pulmonary first-pass effect, the paracrine ‘hit-and-run’ theory, and real trial data for lupus, Crohn’s, and rheumatoid arthritis—plus how 2026 FDA enforcement is reshaping the landscape.
Sickle Cell Therapy Access in 2026: The Uptake Gap Explained
Nearly three years after FDA approval, sickle cell therapy uptake remains strikingly low. This article unpacks the cost barriers, Medicaid rollout challenges, and treatment center shortages creating a gap between cure and access in 2026.
Non-Small Cell Lung Cancer Therapy: The 2026 Treatment Map
Non-small cell lung cancer therapy has evolved into a dynamic continuum spanning surgery, immunotherapy, targeted treatment, and antibody-drug conjugates. This 2026 treatment map breaks down how biomarkers and staging now guide personalized care, plus the cell and gene therapy trials shaping the future. A clear, up-to-date guide for patients, caregivers, and clinicians navigating today’s NSCLC options.
Idaho Regenerative Medicine: Regulation, Risk & Where to Go in 2026
Navigating Idaho regenerative medicine means understanding a regulatory vacuum, the often-misapplied Right to Try Act, and real enforcement cases like the Burst Biologics warning letter. This statewide 2026 guide covers Treasure Valley, Eastern Idaho, and North Idaho, giving patients the regulatory, safety, and insurance context most clinic websites leave out.
Therapy for Sickle Cell Disease: A 2026 Tiered Treatment Guide
This 2026 guide breaks down therapy for sickle cell disease into three clear tiers—supportive care, disease-modifying drugs, and curative options like gene therapy and stem cell transplant. It also covers the latest approvals, safety updates, and pipeline treatments often missing from outdated resources. A practical, up-to-date roadmap for patients and caregivers navigating SCD care.
Myeloma CAR T-Cell Therapy: Choosing Between Abecma and Carvykti
Facing a choice between Abecma and Carvykti for myeloma CAR T-cell therapy? This data-driven guide breaks down eligibility criteria, response rates, and side-effect profiles for both FDA-approved options. Learn what sets these therapies apart so you can have a more informed conversation with your care team.